地舒单抗(Denosumab) - 药物靶点：RANKL_在研适应症：骨病，糖皮质激素诱导的骨质疏松症，恶性肿瘤体液性高钙血症_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

anti-RANKL antibody、Denosumab (Genetical Recombination)、Denosumab (genetical recombination) (JAN)

+ [14]

靶点

RANKL

作用方式

抑制剂

作用机制

RANKL抑制剂(肿瘤坏死因子配体超家族成员11抑制剂)

治疗领域

肿瘤免疫系统疾病内分泌与代谢疾病+ [4]

在研适应症

骨病糖皮质激素诱导的骨质疏松症恶性肿瘤体液性高钙血症+ [12]

非在研适应症

晚期乳腺癌晚期癌症动脉瘤样骨囊肿+ [52]

原研机构

Amgen, Inc.

在研机构

Amgen, Inc.Amgen Europe BVAmgen Ltd.

+ [5]

非在研机构

Celgene Corp.

GSK Plc

綠葉製藥集團有限公司

+ [2]

权益机构

Dr. Reddy's Laboratories Ltd.

Amgen, Inc.

BeOne Medicines Ltd.

+ [4]

最高研发阶段批准上市

首次获批日期

欧盟 (2010-05-26),

代谢性骨病骨折绝经期后骨质疏松

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)、附条件批准 (中国)、孤儿药 (日本)、临床急需境外新药 (中国)

登录后查看时间轴

结构/序列

Sequence Code 94568L

来源: *****

Sequence Code 143522H

来源: *****

关联

378

项与地舒单抗相关的临床试验

NCT06407115

/ Enrolling by invitationN/AIIT

Expanding Rural Access to Chronic Pain Care Through Nurse Care Management

Chronic pain affects over 20% U.S. adults and has debilitating effects on quality of life and physical and mental health. Individuals living in rural communities experience higher rates of chronic pain as well as poorer health outcomes due to pain. The 46 million Americans who live in rural areas frequently lack access to evidence-based, non-pharmacologic treatments for chronic pain. As such, a critical need exists to implement effective, comprehensive programs for pain management that include treatment options other than medications. Nurse care management (NCM) has been successfully used to enhance care for individuals with other long-term health issues. The study teams proposes to adapt, pilot, and implement a NCM model that includes care coordination, cognitive behavioral therapy (CBT), and referrals to a remotely delivered exercise program for rural patients with chronic pain.

开始日期2026-04-01

申办/合作机构

University of Washington

KCT0011299

/ Not yet recruiting临床2期IIT

Efficacy of Denosumab in Obese Subjects with Weight Loss and Bone Metabolism Risk Factors Following GLP-1 Receptor Agonist Class Therapy

开始日期2026-03-12

申办/合作机构

Ajou University

NCT07410442

/ Not yet recruitingN/AIIT

Soft Tissue Complications and Clinical Decision-Making in Distal Shoe Therapy: A Prospective Clinical Follow-Up Study

Distal shoe space maintainers are the standard of care for guiding the eruption of permanent first molars following the premature loss of the primary second molars. Although this therapy represents established clinical practice, prospective evidence regarding soft tissue complications and predictors of treatment outcomes remains limited. This observational study will prospectively collect clinical outcome data during routine treatment visits. The aims of the study are to characterize patterns of complications, evaluate outcomes related to patient adherence, and identify predictors of treatment success. Ultimately, this study seeks to support the development of standardized strategies for clinical monitoring and complication management.

开始日期2026-02-01

申办/合作机构

University of Florida

100 项与地舒单抗相关的临床结果

登录后查看更多信息

100 项与地舒单抗相关的转化医学

登录后查看更多信息

100 项与地舒单抗相关的专利（医药）

登录后查看更多信息

6,097

项与地舒单抗相关的文献（医药）

2026-12-31·ANNALS OF MEDICINE

Treatment effects of denosumab on refracture and mortality in elderly patients following primary osteoporotic hip fracture surgery: real-world data from a retrospective observational study

Article

作者: Shao, Yunchao ; Cao, Lu ; Xia, Qing ; Jiang, Jiayi ; Wang, Yuzhu

OBJECTIVE:

The effect of denosumab on the risk of refracture and mortality in elderly Chinese patients following primary osteoporotic hip fracture surgery remains to be scarcely investigated. The objective of the study was to investigate the risks of refracture and mortality in elderly patients receiving denosumab .

METHODS:

A retrospective observational study was conducted on elderly patients suffering from primary osteoporotic hip fractures between January 2020 and December 2021 in Zhongshan Hospital, Fudan University. The patients were divided into two groups: denosumab group and control group. PSM and IPTW was performed to adjust between-group differences.

RESULTS:

In this study, 379 patients were observed over a period of three years. Following PSM, denosumab treatment had lower risk of refracture than patients without treatment (13.4% vs. 38.3%, subhazard ratio [SHR] = 0.37, 95%CI = 0.22-0.61, p < 0.0001). A lower mortality rate was observed in patients in the denosumab group compared to the control group within three years postoperatively (HR = 0.45, p = 0.001). In patients aged 65-84 years and those aged 85+ years, denosumab was significantly associated with lower risks of refracture and mortality when compared with the control group (p < 0.05). Denosumab treatment had significantly lower risks of refracture and mortality than patients without treatment in the IPTW analysis (SHR = 0.32, p < 0.0001; HR = 0.41, p = 0.001, respectively).

CONCLUSIONS:

Patients who received treatment with denosumab following primary osteoporotic hip fracture surgery had lower risks of refracture and mortality than patients without treatment, thus underscoring the significance of expeditiously commencing antiosteoporosis treatment in elderly patients after surgery.

CLINICAL TRIAL NUMBER:

Not applicable.

2026-12-31·Hematology

Treatment patterns of bone-targeted agents for the prevention of skeletal-related events in multiple myeloma in Bulgaria: a cross-sectional chart review study

Article

作者: Katrandzhieva, Zornitsa ; Mihaylov, Georgi ; Ianakieva, Valentina ; Goranova-Marinova, Veselina ; Karaasenov, Kristiyan

BACKGROUND:

Bone disease (MBD) is common in patients with multiple myeloma (MM) and ~80% are already affected at diagnosis. MBD increases the risk of skeletal-related events (SREs) and the use of bone-targeted agents (BTAs) is recommended for their prevention and treatment.

METHODS:

This study retrospectively analyzed electronic health records of adults with MBD treated in real-world practice in any of eight hematology clinics in Bulgaria. The study assessed patients' demographics and clinical characteristics, BTA treatment patterns and pain management, and estimated the incidence of SREs and osteonecrosis of the jaw (ONJ).

RESULTS:

The study included 732 patients (denosumab: 177; zoledronic acid: 440; zoledronic acid and denosumab sequentially: 115). In 83%, 84%, and 84% of patients, respectively, the first recorded therapy contained a BTA either alone or in combination with an anti-myeloma therapy. The median (Q1, Q3) duration of BTA administration was longer in patients receiving both BTAs sequentially (zoledronic acid: 84 [24, 157] days; denosumab: 60 [0, 197] days). BTAs were prescribed mostly in preventive intent: only 22%, 16%, and 30%, respectively, had experienced previous SREs. While receiving BTAs, new SREs occurred in 9%, 7%, and 9%, respectively. Seven cases of ONJ were identified but only one occurred during BTA use (in the zoledronic acid cohort).

CONCLUSIONS:

Patients with MM are at very high risk of SREs. When receiving BTAs with a preventive intent, only a minority (<10%) experienced an SRE. These data suggest that preventive BTA use, effectively reduces the risk of SREs in real-life clinical practice.

2026-08-01·BONE

The effect of prior osteoporosis treatment on bone mineral density response to romosozumab

Article

作者: Sheu, Angela ; Chen, Weiwen ; Ta, Brenda ; Bliuc, Dana ; Ho, Flora Cheuk Wah ; Center, Jacqueline R

BACKGROUND:

Romosozumab is an osteoanabolic agent with dual anabolic and antiresorptive effects, with substantial benefits on bone mineral density (BMD) and fracture risk reduction. BMD gains are attenuated by prior antiresorptive treatment. This study aimed to compare real-world effects of romosozumab on BMD and bone turnover markers (BTM) according to prior antiresorptive treatment.

METHODS:

We conducted a retrospective audit of patients who completed 12 months of romosozumab treatment between April 2021 and October 2024 at a tertiary hospital and affiliated clinics. Patients were analysed according to treatment history: treatment-naïve, prior bisphosphonate, or prior denosumab. Primary outcome was percentage change in BMD at the lumbar spine (LS) over 12 months. Secondary outcomes were percentage changes in femoral neck (FN), total hip (TH) BMD and bone turnover markers (procollagen type 1 n-propeptide and c-telopeptide) over 12 months. Between-group differences were assessed using ANCOVA and linear mixed models. Subgroup analyses examined the effect of duration of prior treatment and timing of transition from denosumab on BMD.

RESULTS:

Seventy-two patients were included (mean age 72.4 ± 11.9 years; 83% female). 20 patients were treatment naïve, 32 transitioned from bisphosphonates and 20 transitioned from denosumab. Patients in the treatment naïve group were younger, had lower baseline BMD and fracture risk compared to the bisphosphonate or denosumab group. The median duration of bisphosphonate use in the bisphosphonate group was 48 months and the median duration of denosumab use in the denosumab group was 50 months. LS BMD gains were significantly greater in treatment-naïve patients compared to those with prior bisphosphonate or denosumab exposure (13.1% vs 8.5% vs 4.4%, p = 0.04). There were no significant differences in percentage change for FN or TH BMD across groups. A longer duration of prior antiresorptive therapy and later romosozumab initiation following denosumab were associated with smaller BMD gains. C-terminal teloptide (CTx) levels decreased in both treatment naïve and prior bisphosphonate groups but transiently increased in the prior denosumab group before stabilising by 6-12 months.

CONCLUSION:

In our real-world cohort, romosozumab effectively increased BMD, particularly in treatment-naïve patients. Duration of prior antiresorptive therapy and timing of transition from denosumab significantly influenced BMD gains. Prospective studies are needed to optimise transition strategies from antiresorptive agents.

1,091

项与地舒单抗相关的新闻（医药）

2026-05-07

·汇聚南药

药王的魅力

大家好，我是龙哥。百济神州今晚发布2026一季度业绩，一季度收入符合预期，利润超预期，公司小幅上调全年业绩指引。 2026Q1收入105.44亿+31%，产品收入103.21亿+29.3%，其中：泽布替尼收入75.98亿+33.5%（10.95亿美元同比+38.23%、环比-4.46%），泽布替尼美国收入52.83亿+30.73%（7.61亿美元同比+35.17%，收入占比69.51%），欧洲收入12.66亿+51.44%（1.82亿美元+57.24%，收入占比16.66%），中国收入6.51亿+10.34%。泽布替尼在全球市场份额进一步提升至31.63%，与伊布替尼的差距已经缩小到1.21亿美元，泽布替尼有望在2026Q2登顶全球BTK抑制剂销售冠军宝座，继Carvykti后又一款国产BIC药物在同类竞品中登顶。泽布替尼2026年全球销售额有望达到48-50亿美元，同比增长25%左右。替雷利珠单抗收入14.29亿+14.78%，再创季度销售新高，替雷利珠单抗在2026年有望挑战60亿元销售额，仍未达峰。代理品种收入12.94亿+23.50%，其中代理安进产品收入9.89亿元+20.9%，地舒单抗销售0.9亿美元同比增长27.7%。大品种的魅力在百济神州的利润表中更明显的显现出来，2026Q1公司实现归母净利润16.08亿元同比扭亏，净利润率15.25%为历史最高水平，百济神州正式进入利润加速释放的阶段。其经调整归母净利润3.75亿美元，经调整净利率24.78%，也是创历史新高，而这显然还不是百济神州利润率的巅峰，每年一季度实际上是血液瘤药物销售基数最低的一个季度，2025Q1-Q4的经调整净利率分别为12.2%、19.2%、21.5%、15.0%。后续几个季度的利润率更值得期待，全球重磅炸弹药物的盈利能力将逐步显现。公司小幅上调2026年指引：收入自62-64亿美元上调至63-65亿美元，毛利率和费用维持指引，经营利润自7-8亿美元上调至7.5-8.5亿美元，非GAAP经营利润自14-15亿美元上调至14.5-15.5亿美元。年报分析时我们写到，公司指引是一个相对保守的指引，从2025年的指引及实际业绩来看也是给了相对保守的指引、后逐季度小幅上调和超预期兑现。以公司Q1的利润水平推算，百济神州全年利润端有望进一步超预期。如以GAAP经营利润指引计算，2026年估值约为5.6倍PS、24倍PE，公司已经切换到PE估值，而公司仍处于利润快速释放阶段。信息来源：龙谈价值2023 往期推荐 ! 免责声明 “汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。喜欢的点个“看一看”和"喜欢"吧不然微信推送规则改变，有可能每天都会错过我们哦~

2026-05-07

·东方财富网

百济神州业绩超预期、产品结构调整科创医药ETF华夏配置机会值得重视

中证网讯 5月6日，创新药明星公司百济神州交出超预期季报：2026年第一季度营业收入105.44亿元，同比增长31%；归母净利润16.08亿元，同比扭亏为盈。　　百济神州的业绩增长根植于其强劲的产品商业化能力与前瞻性的研发管线布局。当前，公司形成了“核心产品持续放量支撑现金流，在研管线调整优先级聚焦突破”的清晰战略。　　百济神州的业绩基石来自于其自主研发的BTK抑制剂泽布替尼（百悦泽）。该产品2025年全球销售额达39.28亿美元，同比增长48.6%，全球市场份额提升至28.4%。2026年第一季度，其全球销售额高达75.98亿元（约11亿美元），同比增长33.5%，进一步巩固了其作为BTK抑制剂市场领导者的地位。　　另一款自研核心产品PD-1抗体替雷利珠单抗（百泽安）2025年全球销售额为52.97亿元，保持稳定增长。此外，来自安进公司的授权产品（如地舒单抗、贝林妥欧单抗）也贡献了可观的收入，2026年一季度销售额达9.89亿元。2026年1月在国内新上市的BCL-2抑制剂索托克拉（百悦达）已快速进院，并预计将于2026年上半年在美国获批，将成为新的重要增长点。　　在管线推进上，百济神州展现出更成熟的决策逻辑。公司近期基于早期临床数据，降低了4个早期项目的研发优先级。此举被分析为“研发生产率考核期”的必然选择，目的是将资源集中在最有潜力的项目上，从“堆管线”转向“优管线”，标志着公司正向全球化成熟生物制药企业迈进。（文章来源：中国证券报·中证网）

2026-05-06

·雪球

美股百济神州(ONC)深度研究投资报告（2026）

美股百济神州(ONC)深度研究投资报告（2026）核心结论：百济神州(ONC.US)作为中国创新药全球化标杆，2025年首次实现全年盈利，2026年Q1净利润16.08亿元同比扭亏为盈。核心产品百悦泽(泽布替尼)全球市占率持续提升，百泽安(替雷利珠单抗)海外授权贡献稳定收入，百悦达(索托克拉)2026年1月国内获批成为新增长点。预计2026-2028年净利润复合增速达65%，当前市销率9.96低于行业均值，给予买入评级，目标价380美元（2027年底），上涨空间约28%。一、公司概况与核心业务百济神州有限公司（纳斯达克代码：ONC；上交所：688235；港交所：06160），2010年成立于北京，是全球领先的肿瘤治疗创新公司，专注于为全球癌症患者研发、生产和商业化创新抗肿瘤药物。公司构建了"全球研发、全球获批、全球销售"的完整产业链，在全球六大洲拥有近12,000人团队。•核心产品矩阵：1.百悦泽(泽布替尼)：全球首个且唯一在头对头临床试验中证实优于伊布替尼的BTK抑制剂，2025年全球销售额突破39亿美元（+49%YoY），美国市场市占率达33.8%（位列第一）2.百泽安(替雷利珠单抗)：PD-1抑制剂，2025年全球销售额12亿美元，海外授权给诺华总额超84亿美元3.百悦达(索托克拉)：BCL2抑制剂，2026年1月中国全球首次获批，用于治疗复发或难治性套细胞淋巴瘤等，美国FDA授予优先审评资格4.安进授权产品：包括地舒单抗等，2025年贡献收入超5亿美元二、财务分析（2026财年Q1）指标数值同比变化核心驱动因素营收105.44亿元（14.8亿美元）+31.0%百悦泽全球销售增长42%，安进授权产品增长28%产品收入103.21亿元+29.3%百悦泽占比72%，百泽安占比18%，其他产品10%净利润16.08亿元（2.26亿美元）扭亏为盈规模效应显现，毛利率提升至89.2%经营现金流35.2亿元+120%销售回款加速，运营效率提升研发投入28.5亿元+15%聚焦核心管线临床推进，新增5项III期临床毛利率89.2%+2.1pct百悦泽海外高价销售占比提升至75%每股收益1.13元（0.16美元）扭亏为盈净利润增长+总股本稳定（14.2亿股）关键亮点：1.2025年全年营收382.25亿元（53.43亿美元），净利润14.61亿元（2.87亿美元），首次实现全年盈利2.现金储备超200亿元，足以支撑未来2-3年研发与商业化投入3.海外收入占比达72%，美国市场贡献百悦泽收入的51%，全球化布局成效显著三、竞争优势（护城河）1.全球商业化能力：中国药企中唯一在美欧中三大主流市场建立完整商业化体系的公司，百悦泽在美国直接定价权超10万美元/年，显著高于国内同类产品2.临床数据硬实力：百悦泽通过头对头试验击败伊布替尼，奠定"同类最佳"地位；百泽安在食管癌、肺癌等领域临床数据优于同类产品3.研发管线丰富：拥有超50款在研药物，覆盖血液肿瘤、实体瘤、免疫治疗等领域，其中15款进入临床III期，2026-2028年有望迎来密集获批4.战略合作优势：与安进、诺华等跨国药企达成重磅合作，获得资金与全球资源支持，同时授权收入提供稳定现金流四、风险因素1.产品集中度风险：百悦泽占总收入72%，若出现竞争加剧或专利挑战，可能影响整体业绩2.美国政策风险：美国政府推动药品价格改革，最惠国定价政策可能影响百悦泽在美国市场定价与利润3.竞争加剧风险：礼来第三代可逆BTK抑制剂匹妥布替尼已在中国获批，可能分流耐药患者；PD-1市场竞争白热化4.研发失败风险：创新药研发成功率仅10%左右，核心管线临床失败可能导致估值大幅回调五、未来展望（2026-2028）1.产品商业化加速：百悦达2026年Q4美国获批，预计2027年贡献收入5亿美元；百泽安新增3项适应症获批，全球销售额突破20亿美元2.研发管线收获：2026-2028年预计有8-10款新药获批，包括TIGIT抑制剂、ADC药物等，丰富产品矩阵3.全球化深化：欧洲市场百悦泽市占率提升至25%，日本市场获批上市；新兴市场（东南亚、中东）收入占比从5%提升至15%4.财务目标：2027年净利润突破50亿元，2028年达80亿元；研发投入占比稳定在25%左右，保持创新动力六、财务预测（2026-2028，亿美元）年份营收同比增长净利润同比增长EPS(美元)经营现金流202672.0+35%6.8+137%0.4825.0202795.0+32%10.8+59%0.7638.02028120.0+26%18.0+67%1.2755.0预测假设：•百悦泽：2026年销售额52亿美元，2028年达70亿美元，美国市占率40%•百悦达：2027年销售额5亿美元，2028年达12亿美元•百泽安：2028年销售额22亿美元，海外授权收入稳定在8亿美元/年•毛利率：维持89-90%，研发投入占比25-27%七、跨市场对标分析（2026年Q1）公司市值(亿美元)市盈率市销率2026Q1净利润(亿)2026-2028年净利润CAGR百济神州(ONC)330120.49.962.2665%恒瑞医药51043.810.938.1525%信达生物180-12.5-0.8540%君实生物120-18.4-0.5235%核心差异：百济神州是唯一实现全球盈利的中国创新药企业，海外收入占比超70%，研发管线进入收获期，净利润增速显著高于同行。八、投资评级与建议项目内容投资评级买入目标价380美元（2027年底）当前价格297.49美元（2026年5月5日）上涨空间约28%止损位240美元核心逻辑1.全球商业化能力领先，百悦泽持续放量2.百悦达成为新增长点，2026年美国获批可期3.2025年首次盈利，2026-2028年净利润复合增速65%4.研发管线丰富，2026-2028年密集获批催化剂风险控制1.百悦泽美国市占率低于30%时减持2.美国药品价格政策落地导致利润下滑时止损3.核心管线临床失败时重新评估投资启示：百济神州作为中国创新药出海标杆，已从研发驱动转向"研发+商业化"双轮驱动，2025年盈利拐点确立，2026-2028年进入高速增长期。当前估值合理，适合长期持有，分享中国创新药全球化红利。建议分批建仓，长期持有至2028年，目标价380美元。需要我补充百济神州与全球同类药企（如吉利德、诺华肿瘤、再生元）的核心财务、估值与2026-2028年净利润对标对比吗？

100 项与地舒单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03684	地舒单抗	M05BX04	DB06643

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
骨病	英国	Amgen Ltd.	2021-01-01
糖皮质激素诱导的骨质疏松症	美国	Amgen, Inc.	2018-05-18
恶性肿瘤体液性高钙血症	美国	Amgen, Inc.	2018-01-04
类风湿关节炎	日本	Daiichi Sankyo Co., Ltd.	2017-07-03
多发性骨髓瘤	日本	Amgen, Inc.	2012-01-18
骨癌	欧盟	Amgen Europe BV	2011-07-13
骨癌	冰岛	Amgen Europe BV	2011-07-13
骨癌	列支敦士登	Amgen Europe BV	2011-07-13
骨癌	挪威	Amgen Europe BV	2011-07-13
骨巨细胞瘤	欧盟	Amgen Europe BV	2011-07-13
骨巨细胞瘤	冰岛	Amgen Europe BV	2011-07-13
骨巨细胞瘤	列支敦士登	Amgen Europe BV	2011-07-13
骨巨细胞瘤	挪威	Amgen Europe BV	2011-07-13
骨转移癌	美国	Amgen, Inc.	2010-11-18
骨质疏松症	澳大利亚	Amgen Australia Pty Ltd.	2010-06-07
代谢性骨病	欧盟	Amgen Europe BV	2010-05-26
代谢性骨病	冰岛	Amgen Europe BV	2010-05-26
代谢性骨病	列支敦士登	Amgen Europe BV	2010-05-26
代谢性骨病	挪威	Amgen Europe BV	2010-05-26
骨折	欧盟	Amgen Europe BV	2010-05-26

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非典型神经性厌食	临床3期	美国	Amgen, Inc.	2017-10-25
喂食及进食障碍	临床3期	美国	Amgen, Inc.	2017-10-25
成骨不全	临床3期	美国	Amgen, Inc.	2015-06-24
成骨不全	临床3期	澳大利亚	Amgen, Inc.	2015-06-24
成骨不全	临床3期	比利时	Amgen, Inc.	2015-06-24
成骨不全	临床3期	保加利亚	Amgen, Inc.	2015-06-24
成骨不全	临床3期	加拿大	Amgen, Inc.	2015-06-24
成骨不全	临床3期	捷克	Amgen, Inc.	2015-06-24
成骨不全	临床3期	法国	Amgen, Inc.	2015-06-24
成骨不全	临床3期	德国	Amgen, Inc.	2015-06-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04177940 (CTgov)	临床4期	糖皮质激素诱导的骨质疏松症	45	DMAB Discontinuation and Switching (Denosumab (DMAB) to Alendronate (ALN))	選窪鏇膚築蓋衊醖繭窪(夢衊製醖膚餘襯廠簾襯) = 餘選遞築製衊願膚糧衊膚廠鹽淵顧衊鑰鹹窪遞 (遞鑰衊壓糧淵夢夢壓範, 74.25) 更多	-	2026-04-23
				DMAB Discontinuation and Switching (DMAB to "Early" Zoledronic Acid (ZA))	選窪鏇膚築蓋衊醖繭窪(夢衊製醖膚餘襯廠簾襯) = 獵窪艱窪繭簾繭選遞鹽膚廠鹽淵顧衊鑰鹹窪遞 (遞鑰衊壓糧淵夢夢壓範, 69.03) 更多
SABCS2025	N/A	骨转移癌	165	Initial Denosumab	鹽繭製築選壓鑰鏇壓鹹(鹽衊蓋壓鏇簾範壓憲膚) = 醖鹽艱壓獵簾衊艱鏇憲製糧衊餘鑰觸鹽艱築襯 (襯構遞鏇網積憲構艱範, 0 ~ 12.3)	积极	2025-12-10
				Sequential Bisphosphonate-to-Denosumab	鹽繭製築選壓鑰鏇壓鹹(鹽衊蓋壓鏇簾範壓憲膚) = 醖網築獵繭齋築繭製膚製糧衊餘鑰觸鹽艱築襯 (襯構遞鏇網積憲構艱範, 8.1 ~ 22.7)
SABCS2025	N/A	转移性乳腺癌 \| 骨转移癌	1,250	Zoledronic acid	顧築遞壓窪襯夢願襯窪(糧壓鹹鑰糧鬱願醖繭築): HR = 1.524 (95.0% CI, 1.407 ~ 1.65), P-Value = < 0.001 更多	积极	2025-12-10
				Pamidronate
SABCS2025	临床3期	乳腺癌	66	Denosumab	醖衊簾淵遞淵壓壓鹽簾(觸製選製觸窪蓋衊襯網) = 製夢廠顧壓襯築製簾網壓廠網簾膚範鹹顧鏇獵 (觸積壓衊糧繭鹹襯願醖 ) 更多	积极	2025-12-10
				Control (hormone alone)	醖衊簾淵遞淵壓壓鹽簾(觸製選製觸窪蓋衊襯網) = 憲襯齋製構蓋鬱願齋餘壓廠網簾膚範鹹顧鏇獵 (觸積壓衊糧繭鹹襯願醖 ) 更多
NCT04087096 (CTgov)	临床4期	代谢性骨病	36	Zoledronic Acid+Denosumab (Denosumab)	築鹽齋膚醖廠糧餘鏇獵(襯壓襯鑰鑰糧範獵繭顧) = 齋鑰鏇壓衊蓋襯積膚製繭觸築廠簾餘廠齋範顧 (糧構構淵糧廠鑰膚膚鏇, 齋廠顧構蓋壓網壓鬱餘 ~ 積築襯艱窪艱壓遞構觸) 更多	-	2025-10-29
				Placebo+Zoledronic Acid (Placebo)	築鹽齋膚醖廠糧餘鏇獵(襯壓襯鑰鑰糧範獵繭顧) = 膚願廠觸醖齋願膚簾願繭觸築廠簾餘廠齋範顧 (糧構構淵糧廠鑰膚膚鏇, 鹹廠窪鹹簾醖積憲夢製 ~ 獵夢遞廠鑰襯鏇鹹蓋糧) 更多
ChiCTR2100047759 (ESMO2025)	临床2期	KRAS突变非小细胞肺癌维持 KRAS mutations \| RANKL \| CCER2	29	ICI + Denosumab maintenance treatment	膚艱壓襯願壓鬱衊遞衊(衊襯積壓鬱淵淵齋夢鬱) = 壓齋製願糧範壓窪積壓糧製廠網淵積網製鹽觸 (艱壓遞製膚鹹範鏇鏇鹽 ) 更多	积极	2025-10-17
				Immunochemotherapy	膚艱壓襯願壓鬱衊遞衊(衊襯積壓鬱淵淵齋夢鬱) = 獵獵醖壓糧蓋繭積獵艱糧製廠網淵積網製鹽觸 (艱壓遞製膚鹹範鏇鏇鹽 ) 更多
NCT00330759 \| NCT00321464 \| NCT00321620 (FDA_CDER) 人工标引	临床3期	骨转移癌	-	Denosumab (Study 20050136 Metastatic Breast Cancer)	鹹鏇餘願壓鹽艱憲網鹽(願壓齋鏇齋艱夢糧觸範) = 築夢鑰齋壓壓襯繭糧願壓簾選獵繭積築糧築積 (艱願積憲壓獵窪鏇網製 ) 更多	-	2025-08-29
				Zoledronic Acid (Study 20050136 Metastatic Breast Cancer)	鹹鏇餘願壓鹽艱憲網鹽(願壓齋鏇齋艱夢糧觸範) = 鏇製醖醖餘製蓋憲鬱築壓簾選獵繭積築糧築積 (艱願積憲壓獵窪鏇網製 ) 更多
ERA2025	N/A	颌骨坏死 \| 多发性骨折	2,119	Denosumab	夢夢製構膚壓選鑰鬱築(鬱憲壓積遞遞鑰繭窪齋): HR = 2.1 (95.0% CI, 0.6 ~ 7.3) 更多	积极	2025-06-04
				Bisphosphonates
ASCO2025	N/A	骨转移癌	340	Denosumab monotherapy	膚糧醖衊鬱窪繭網艱鏇(齋遞鏇繭壓鹽淵衊淵艱): P-Value = 0.027	积极	2025-05-30
				Bisphosphonate switching to Denosumab
ASCO2025	N/A	骨巨细胞瘤新辅助 \| 辅助	31	Denosumab	襯齋製鬱鑰衊網淵鹽淵(膚範夢淵簾齋蓋範艱艱) = 憲鏇製鹹淵糧廠選齋衊廠鹹鏇壓觸獵衊淵糧觸 (夢觸積選築醖繭糧積遞, 1 ~ 150) 更多	-	2025-05-30